RT Journal Article
T1 Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry
A1 Santoro, Francesco
A1 Nunez-Gil, Ivan Javier
A1 Vitale, Enrica
A1 Viana-Llamas, Maria C.
A1 Reche-Martinez, Begona
A1 Romero-Pareja, Rodolfo
A1 Feltez Guzman, Gisela
A1 Fernandez Rozas, Inmaculada
A1 Uribarri, Aitor
A1 Becerra-Munoz, Victor Manuel
A1 Alfonso-Rodriguez, Emilio
A1 Garcia-Aguado, Marcos
A1 Huang, Jia
A1 Ortega-Armas, Maria Elizabeth
A1 Garcia Prieto, Juan F.
A1 Corral Rubio, Eva Maria
A1 Ugo, Fabrizio
A1 Bianco, Matteo
A1 Mulet, Alba
A1 Raposeiras-Roubin, Sergio
A1 Jativa Mendez, Jorge Luis
A1 Espejo Paeres, Carolina
A1 Albarran, Adrian Rodriguez
A1 Marin, Francisco
A1 Guerra, Federico
A1 Akin, Ibrahim
A1 Cortese, Bernardo
A1 Ramakrishna, Harish
A1 Macaya, Carlos
A1 Fernandez-Ortiz, Antonio
A1 Brunetti, Natale Daniele
K1 COVID-19
K1 pharmacology
K1 clinical
K1 Coronavirus disease 2019
AB Background Standard therapy for COVID-19 is continuously evolving. Autopsy studies showed high prevalence of platelet-fibrin-rich microthrombi in several organs. The aim of the study was therefore to evaluate the safety and efficacy of antiplatelet therapy (APT) in hospitalised patients with COVID-19 and its impact on survival.Methods 7824 consecutive patients with COVID-19 were enrolled in a multicentre international prospective registry (Health Outcome Predictive Evaluation-COVID-19 Registry). Clinical data and in-hospital complications were recorded. Data on APT, including aspirin and other antiplatelet drugs, were obtained for each patient.Results During hospitalisation, 730 (9%) patients received single APT (93%, n=680) or dual APT (7%, n=50). Patients treated with APT were older (74 +/- 12 years vs 63 +/- 17 years, p
PB Bmj publishing group
SN 1355-6037
YR 2021
FD 2021-10-05
LK https://hdl.handle.net/10668/26896
UL https://hdl.handle.net/10668/26896
LA en
DS RISalud
RD Apr 5, 2025